TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19318954

Group type: EXPERIMENTAL
Intervention: Exercise training for 4 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary controls (8 subjects)
Number of subjects: 16
Study: 18332267

Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg for 10 minutes, followed by 2 mg/kg 15 minutes later if AF was not terminated)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 16116152

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem-cell rescue
Number of subjects: 560

Group type: COMPARATOR
Intervention: Standard chemotherapy (for infants)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: High-dose therapy
Number of subjects: 560
Study: 12100793

Group type: EXPERIMENTAL
Intervention: Telecare (n=27)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional care (n=16)
Number of subjects: 43
Study: 10366368

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2
Study: 7495598

Group type: EXPERIMENTAL
Intervention: Self-administered survey about risk factors for HIV infection
Number of subjects: 1030
Study: 2249115

Group type: EXPERIMENTAL
Intervention: Oxybutynin hydrochloride (3 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 7357798

Group type: EXPERIMENTAL
Intervention: Levodopa, 1,000 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Levodopa, 1,000 mg and Metoclopramide, 10 mg
Number of subjects: 7
Study: 30321486

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 10 °C for 10 minutes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CON: 30 min seated)
Number of subjects: 22
Study: 27784824

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 25402618

Group type: EXPERIMENTAL
Intervention: Telephone counseling (17 calls over 12 months)
Number of subjects: 115
Study: 24628624

Group type: EXPERIMENTAL
Intervention: Proposed method of uvular repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional method of uvular repair
Number of subjects: 60
Study: 22465220

Group type: EXPERIMENTAL
Intervention: Total urinary resveratrol metabolites (TRMs)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: TRMs adjusted for alcohol
Number of subjects: 1000
Study: 20037568

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBM) 300-1600 mg/day (mean 700±120 mg/day) for 25.43±2.34 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OCB) 600-1800 mg/day (mean 900±145 mg/day) for 12±0.65 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carbamazepine (CBM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oxcarbazepine (OCB)
Number of subjects: 48
Study: 17324224

Group type: EXPERIMENTAL
Intervention: 500 mg levetiracetam
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1500 mg levetiracetam
Number of subjects: 26
Study: 15505444

Group type: EXPERIMENTAL
Intervention: Propofol at a target concentration of 3 microg/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol titrated to maintain a BIS value of 40-50
Number of subjects: 40
Study: 11581136

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 381

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 381
Study: 9768800

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol plus alfentanil 50 ng/mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol plus alfentanil 100 ng/mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no alfentanil)
Number of subjects: 40
Study: 7924364

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ringer's acetate solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trometamol (tris)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbicarb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tris buffer mixture (Tribonate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate and tris buffer mixture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buffers that were not producing CO2
Number of subjects: 0
Study: 3241274

Group type: EXPERIMENTAL
Intervention: CaCO3 at 20 mmol/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31901097

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31190657

Group type: EXPERIMENTAL
Intervention: Socio-demographic and anthropometric characteristics
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Worksite, age, BMI, marital status
Number of subjects: 678
Study: 27799020

Group type: EXPERIMENTAL
Intervention: Any psychotherapy services
Number of subjects: 6884

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy services
Number of subjects: 6884
Study: 25618173

Group type: EXPERIMENTAL
Intervention: Tegafur gimeracil oteracil combined with THP and DDP
Number of subjects: 70

Group type: COMPARATOR
Intervention: THP and DDP (Control)
Number of subjects: 70
Study: 23272664

Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval training (AIT) at 90% of max HR for 4×4 minutes, three times per week for 10 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moderate continuous training (MCT) at 70% of max HR for 47 minutes, three times per week for 10 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy controls (age- and sex-matched individuals)
Number of subjects: 17
Study: 21700302

Group type: EXPERIMENTAL
Intervention: High-intensity exercise combined with a low-sugar diet
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise combined with a low-sugar diet
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard low-fat diet with daily walking (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 75
Study: 18190687

Group type: EXPERIMENTAL
Intervention: Patients indicating interest in speaking to a specialist smoking adviser
Number of subjects: 6856

Group type: EXPERIMENTAL
Intervention: Socioeconomic status measured by the Townsend Index
Number of subjects: 6856

Group type: EXPERIMENTAL
Intervention: Recorded smoking status
Number of subjects: 6856

Group type: EXPERIMENTAL
Intervention: Respondents with no recorded smoking status
Number of subjects: 6856

Group type: EXPERIMENTAL
Intervention: Recorded smokers who responded to the questionnaire
Number of subjects: 6856
Study: 17140886

Group type: EXPERIMENTAL
Intervention: Bridging fibrosis
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Platelet count >150,000/mm(3)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Lower platelet count, higher bilirubin, and INR
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: African American race and female sex
Number of subjects: 1016
Study: 14572503

Group type: EXPERIMENTAL
Intervention: Temazepam (with or without alcohol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol (with or without temazepam)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Temazepam only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol and temazepam combined
Number of subjects: 24
Study: 10671807

Group type: EXPERIMENTAL
Intervention: Endurance training (walking 3 days/week at 70% HRR, starting at 20 min and increasing to 50 min by week 3)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (maintained normal activity)
Number of subjects: 29
Study: 9083908

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily (days 0-28) plus amoxycillin 500 mg three times daily (days 15-28)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (matched to amoxycillin) three times a day (days 0-14) followed by placebo (days 15-28)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lansoprazole plus amoxycillin
Number of subjects: 101
Study: 8472521

Group type: EXPERIMENTAL
Intervention: ST-679 (1200 mg single oral dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paracetamol (1000 mg single oral dose)
Number of subjects: 40
Study: 3704665

Group type: EXPERIMENTAL
Intervention: Phlebotomy alone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Myelosuppressive agents (32P or chlorambucil) supplemented by phlebotomy
Number of subjects: 1000
Study: 29456079

Group type: COMPARATOR
Intervention: PEG‐IFN alfa‐2a + placebo
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2a + ETV
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2a + ADV
Number of subjects: 280
Study: 26962303

Group type: EXPERIMENTAL
Intervention: MIPS
Number of subjects: 12
Study: 26341154

Group type: EXPERIMENTAL
Intervention: Accelerated Gufoni maneuver (faster position changing within 1s)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-accelerated Gufoni maneuver (slower maneuvers)
Number of subjects: 50
Study: 24045030

Group type: EXPERIMENTAL
Intervention: Days of heroin use in the last month
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cocaine, cannabis, cigarettes, alcohol use, unintentional overdose, injection drug use
Number of subjects: 112
Study: 19945275

Group type: EXPERIMENTAL
Intervention: Granisetron 3mg i.v.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ondansetron 8 mg i.v.
Number of subjects: 80
Study: 19083391

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (250 mL daily for 4 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Apple juice (250 mL daily for 4 weeks)
Number of subjects: 26
Study: 16176059

Group type: EXPERIMENTAL
Intervention: Urban females
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Rural females
Number of subjects: 1700
Study: 12614835

Group type: EXPERIMENTAL
Intervention: group‐based cognitive‐behavioral stress management/expressive‐supportive therapy intervention (CBSM+)
Number of subjects: 330

Group type: COMPARATOR
Intervention: individual psychoeducation condition
Number of subjects: 330
Study: 10852273

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections (40 mg of 6‐methylprednisolone acetate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1 ml saline solution)
Number of subjects: 20
Study: 9165957

Group type: EXPERIMENTAL
Intervention: Sevoflurane in nitrous oxide and oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane in oxygen alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol infusion
Number of subjects: 0
Study: 1376797

Group type: EXPERIMENTAL
Intervention: Isradipine (ISR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2932722

Group type: EXPERIMENTAL
Intervention: Automated analyser for bacterial identification and susceptibility testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimizing information transfer from laboratory to ward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earlier results of susceptibility testing
Number of subjects: 0
Study: 29088030

Group type: EXPERIMENTAL
Intervention: Biannual mass azithromycin distribution (6 distributions to children <12 years of age)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Annual mass azithromycin distribution (3 distributions to the entire community)
Number of subjects: 24
Study: 27931257

Group type: EXPERIMENTAL
Intervention: Fluoride varnish program (semi-annual applications since age 1)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Standard oral health program (without fluoride varnish)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Caries presence
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Caries-free children
Number of subjects: 507
Study: 24666361

Group type: EXPERIMENTAL
Intervention: Topical tretinoin cream 0.1%
Number of subjects: 324
Study: 22519942

Group type: EXPERIMENTAL
Intervention: Dräger V500 ventilator interface
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dräger Evita 4 ventilator interface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific training episode
Number of subjects: 0
Study: 20230295

Group type: EXPERIMENTAL
Intervention: Low-frequency magnetic field exposure in healthy subjects
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Low-frequency magnetic field exposure in diabetic patients
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham exposure in diabetic patients
Number of subjects: 81
Study: 17999710

Group type: EXPERIMENTAL
Intervention: Pacing-induced heart rate changes in CAD patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pacing-induced heart rate changes in non-CAD patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Detection of myocardial ischemia using STC-VM
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: STC-VM at 54 microV
Number of subjects: 45
Study: 11732859

Group type: EXPERIMENTAL
Intervention: T/T genotype of the 5-HT2A receptor gene
Number of subjects: 58

Group type: COMPARATOR
Intervention: C/C and C/T genotypes of the 5-HT2A receptor gene
Number of subjects: 58
Study: 9231537

Group type: EXPERIMENTAL
Intervention: Automated voice‐interactive program (CES-D) via cellular telephone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Face‐to‐face method (CES-D)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both methods (CES-D)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Automated CES-D
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Verbal response latency time
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Acculturation levels of Spanish speakers
Number of subjects: 55
Study: 8231041

Group type: EXPERIMENTAL
Intervention: IOL with laser ridge
Number of subjects: 100

Group type: COMPARATOR
Intervention: IOL without laser ridge
Number of subjects: 100
Study: 2891519

Group type: EXPERIMENTAL
Intervention: Hormonal treatment (LH‐RH, LH‐RH plus hCG)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: New course of hCG
Number of subjects: 37
Study: 30854987

Group type: EXPERIMENTAL
Intervention: Life History Calendar (LHC)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard retrospective diagnostic interview without LHC
Number of subjects: 1000
Study: 30324710

Group type: EXPERIMENTAL
Intervention: Group-based social skills training SOSTA-FRA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 27314247

Group type: EXPERIMENTAL
Intervention: Cranberry extract (PAC‐Aproanthocyanidin‐A), 36 patients, administered for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo, 36 patients, administered for 12 weeks
Number of subjects: 72
Study: 25604206

Group type: EXPERIMENTAL
Intervention: Extended Internet-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal Internet-based intervention
Number of subjects: 0
Study: 23674791

Group type: EXPERIMENTAL
Intervention: Split-bolus spectral CT protocol (60 keV)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard CT protocol (pancreatic phase)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard CT protocol (portal venous phase)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard CT protocol
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Split-bolus spectral CT protocol
Number of subjects: 163
Study: 20873899

Group type: EXPERIMENTAL
Intervention: Last-session alliances
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Third-session alliances
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Couple alliances that started over the mean and increased
Number of subjects: 250
Study: 18853053

Group type: EXPERIMENTAL
Intervention: Prilocaine 3% associated with felypressin 0.03 IU/ml
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lidocaine 2% without vasoconstrictor
Number of subjects: 65
Study: 16801691

Group type: EXPERIMENTAL
Intervention: Air-Stirrup brace combined with elastic wrap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Air-Stirrup brace or walking cast for 10 days followed by bracing
Number of subjects: 0

Group type: COMPARATOR
Intervention: All treatments (Air-Stirrup brace, elastic wrap, walking cast)
Number of subjects: 0
Study: 12891281

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atorvastatin (combined 10 mg and 40 mg)
Number of subjects: 90
Study: 10974131

Group type: EXPERIMENTAL
Intervention: 150 microg of testosterone per day transdermally
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 300 microg of testosterone per day transdermally
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8604904

Group type: EXPERIMENTAL
Intervention: Open tension-free hernioplasty procedure
Number of subjects: 2953

Group type: COMPARATOR
Intervention: Laparoscopic repair
Number of subjects: 2953
Study: 1593412

Group type: EXPERIMENTAL
Intervention: Pulsated jet irrigator with saline solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Syringe with saline solution
Number of subjects: 10
Study: 31321423

Group type: EXPERIMENTAL
Intervention: Complete substitution (CS; 'avoid cigarettes')
Number of subjects: 150

Group type: COMPARATOR
Intervention: Partial substitution (PS; 'use snus as you like with your cigarettes')
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual brand cigarettes (UB)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Complete substitution (CS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study: 30728061

Group type: EXPERIMENTAL
Intervention: Citrus Aurantium + Caffeine (CA + C) 100 mg of CA and 100 mg of C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Citrus Aurantium + Caffeine (CA + C)
Number of subjects: 10
Study: 27998025

Group type: EXPERIMENTAL
Intervention: TCA peel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: dermapen machine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 30
Study: 27434441

Group type: EXPERIMENTAL
Intervention: Buprenorphine implants (80 mg, 4 implants)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sublingual buprenorphine (8 mg/d or less) with placebo implants
Number of subjects: 177
Study: 24400915

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 308

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 308
Study: 22241281

Group type: EXPERIMENTAL
Intervention: 400 mg amisulpride
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 10 mg aripiprazole
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 2 mg risperidone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 18679683

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate-impregnated wound dressing
Number of subjects: 601

Group type: COMPARATOR
Intervention: Standard sterile dressing
Number of subjects: 601
Study: 18665060

Group type: EXPERIMENTAL
Intervention: Physicians with higher openness to feelings
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Physicians who are more dutiful or rule-bound
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Physicians reporting more anxious vulnerability
Number of subjects: 46
Study: 15569821

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg per day for 5 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 16
Study: 12572702

Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (CT) screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incidence screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy before surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy following surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) scanning
Number of subjects: 0
Study: 10469812

Group type: EXPERIMENTAL
Intervention: Prescription for 2 quarts of ORS filled for free at on-site pharmacy plus written instructions
Number of subjects: 479

Group type: COMPARATOR
Intervention: Written instructions alone
Number of subjects: 479
Study: 8912770

Group type: EXPERIMENTAL
Intervention: Patients with obstructive sleep apnea (OSA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 19
Study: 1859751

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.1 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg kg‐1 (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neostigmine vs Edrophonium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Doubling doses of anticholinesterases
Number of subjects: 30
Study: 6336923

Group type: EXPERIMENTAL
Intervention: Pneumatic trousers
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Pneumatic trousers (VF)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Pneumatic trousers (PIVR)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Pneumatic trousers (AS)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (VF)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (PIVR)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (AS)
Number of subjects: 136
Study: 31524782

Group type: EXPERIMENTAL
Intervention: 1:8 work-to-rest ratio
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1:10 work-to-rest ratio
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1:12 work-to-rest ratio
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 36